Zobrazeno 1 - 10
of 460
pro vyhledávání: '"Sodium glucose co-transporter 2 inhibitor"'
Autor:
Sunagawa K, Hirai K, Sunagawa S, Kamiya N, Komesu I, Sunagawa Y, Sunagawa H, Nakachi K, Hirai A, Ookawara S, Morishita Y
Publikováno v:
Diabetes, Metabolic Syndrome and Obesity, Vol Volume 17, Pp 3767-3781 (2024)
Kae Sunagawa,1,2 Keiji Hirai,3 Sumito Sunagawa,1,2 Norifumi Kamiya,1 Isao Komesu,1 Yusako Sunagawa,1 Hiroshi Sunagawa,1 Ken Nakachi,4 Aizan Hirai,5 Susumu Ookawara,3 Yoshiyuki Morishita3 1Sunagawa Medical Clinic, Okinawa, Japan; 2Division of Endocrin
Externí odkaz:
https://doaj.org/article/310c83a1ef4f4dd4a7012a977f9d4501
Autor:
Masahiro Isogawa, Hisashi Makino, Cheol Son, Kunihiro Nishimura, Takumi Hirata, Shu Kasama, Yoshihiro Miyamoto, Michio Noguchi, Masato Kasahara, Kiminori Hosoda
Publikováno v:
BMC Endocrine Disorders, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background While the Sodium-glucose co-transporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP4) are widely used for the glycemic control in type 2 diabetes mellitus, the differences in the effects of SGLT2 inhibitors and DPP4 inhib
Externí odkaz:
https://doaj.org/article/3c30aa10af6145a49ad751da66897f47
Publikováno v:
Indian Heart Journal, Vol 76, Iss 4, Pp 229-239 (2024)
Novel therapies for heart failure with reduced ejection fraction (HFrEF) are angiotensin receptor-neprilysin inhibitor (ARNI), sodium-glucose co-transporter 2 inhibitor (SGLT2i), etc. The purpose of this review is to determine the effects of ARNI and
Externí odkaz:
https://doaj.org/article/2d882cf8746c4bb6be1524357dc77b6b
Publikováno v:
Journal of Veterinary Internal Medicine, Vol 37, Iss 6, Pp 2520-2528 (2023)
Abstract Background Decreasing hyperinsulinemia is crucial in preventing laminitis in insulin dysregulated (ID) horses. Complementary pharmacological treatments that efficiently decrease postprandial hyperinsulinemia in ID horses are needed. Objectiv
Externí odkaz:
https://doaj.org/article/ec181aa4d11c44c8b3a7c22177c862e5
Publikováno v:
Cardiovascular Diabetology, Vol 22, Iss 1, Pp 1-13 (2023)
Abstract Background This study aimed to reveal the prevalence of sodium-glucose co-transporter 2 (SGLT2) inhibitor treatment and its association with restenosis risk in patients with diabetes mellitus undergoing endovascular therapy for symptomatic p
Externí odkaz:
https://doaj.org/article/88966c30d2444359b0acec8ec0dfebe5
Autor:
Odette S. Reifsnider, Ali Tafazzoli, Stephan Linden, Jack Ishak, Pal Rakonczai, Matthew Stargardter, Effie Kuti
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 4 (2024)
Background In the EMPEROR‐Reduced trial (Empagliflozin Outcome Trial in Patients with Chronic Heart Failure and a Reduced Ejection Fraction), empagliflozin plus standard of care reduced the composite of cardiovascular death or hospitalization for h
Externí odkaz:
https://doaj.org/article/8be347aa15bf47fe965fc52f141023d4
Autor:
Xiaoling Li, Mengnan Wang, Jan-Ole Kalina, Benedikt Preckel, Markus W. Hollmann, Martin Albrecht, Coert J. Zuurbier, Nina C. Weber
Publikováno v:
Redox Biology, Vol 69, Iss , Pp 102979- (2024)
Background: Empagliflozin (EMPA) ameliorates reactive oxygen species (ROS) generation in human endothelial cells (ECs) exposed to 10 % stretch, but the underlying mechanisms are still unclear. Pathological stretch is supposed to stimulate protein kin
Externí odkaz:
https://doaj.org/article/2f33de2efafb4ef0b4548402cf79295b
Autor:
Atsushi Tanaka, Takumi Imai, Shigeru Toyoda, Kazuhiro Sugimoto, Ruka Yoshida, Machi Furuta, Koichi Node, the PROTECT Investigators
Publikováno v:
Diabetology & Metabolic Syndrome, Vol 15, Iss 1, Pp 1-11 (2023)
Abstract Backgrounds/Aim Recent studies have shown that the addition of sodium-glucose co-transporter 2 (SGLT2) inhibitors gradually reduces the estimated fluid volume parameters in a broad range of patient populations, suggesting that this mediates
Externí odkaz:
https://doaj.org/article/d847f9b4700d47ea961043b8d4623dc0
Autor:
Lin Zhang, Heming Zhang, Xiuzhu Xie, Ruping Tie, Xiaolin Shang, Qianqian Zhao, Junjie Xu, Liyuan Jin, Jinying Zhang, Ping Ye
Publikováno v:
Diabetology & Metabolic Syndrome, Vol 15, Iss 1, Pp 1-14 (2023)
Abstract Background Empagliflozin, a sodium–glucose co-transporter 2 inhibitor (SGLT2i), has been reported to significantly reduce the risk of heart failure in multiple clinical studies. However, the underlying mechanisms remain elusive. This study
Externí odkaz:
https://doaj.org/article/252becbc327c49f68e6f451720f1c5f6
Publikováno v:
Diabetology & Metabolic Syndrome, Vol 15, Iss 1, Pp 1-8 (2023)
Abstract Background Glycemic monitoring has become critical during the COVID-19 pandemic because of poor prognosis in diabetes. Vaccines were key in reducing the spread of infection and disease severity but data were lacking on effects on blood sugar
Externí odkaz:
https://doaj.org/article/d449a606a39f4616addc8d0fb61e1932